Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2022

Genmab — November 2022

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #970

    Link Preview Image
    Genmab Option Alert: May 19 $50 Calls at the Ask: 148 @ $4.1 vs 4 OI; Ref=$45.6 - Genmab (NASDAQ:GMAB)

    favicon

    Benzinga (www.benzinga.com)

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #971

      Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia https://www.frontiersin.org/articles/10.3389/fimmu.2022.1055473/full

      1 Reply Last reply
      0
      • Legolas23L Offline
        Legolas23L Offline
        Legolas23
        wrote on sidst redigeret af
        #972

        @El I think we nailed the CWH and SHS reverse. Good job ,-)

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #973

          it is slightly different GB - Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley -Morgan Stanley analyst Matthew Harrison names Genmab (GMAB) a "Catalyst Driving Idea" while keeping an Underweight rating on the shares with a $34 price target. Genmab and Johnson & Johnson (JNJ) are in a second arbitration over Darzalex Faspro and a ruling is expected in 2023. The analyst reviewed the redacted copy of the license agreement and believes Genmab "may have a valid claim."

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #974

            The license agreement states that the milestone payments and royalties are paid on a licensed product-by-licensed product basis, and for each licensed product, royalty payments shall commence on the date of the first commercial sale of such licensed product and expiring on the later of 13 years thereafter or the expiration of relevant patents, Harrison tells investors in a research note. He says the key issue is whether Genmab is entitled to additional milestone payments and a new 13-year

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #975

              royalty term from Darzalex Faspro's first commercial sale date. Harrison views Genmab's risk/reward as favorable into the 2023 ruling.

              Just a moment...

              favicon

              (thefly.com)

              1 Reply Last reply
              0
              • G Offline
                G Offline
                GeorgeBest
                wrote on sidst redigeret af
                #976

                Okay, thanks for the clarification EL. Looks quite promissing then. But but but…

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #977

                  the real difficult job is to determine where it will stop @Legolas 😉

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #978

                    agree lol, but but but 😉 i am not hoping on anything either

                    1 Reply Last reply
                    0
                    • Legolas23L Offline
                      Legolas23L Offline
                      Legolas23
                      wrote on sidst redigeret af
                      #979

                      Agree, but anyway...we saw it - he he .-)

                      1 Reply Last reply
                      0
                      • H Offline
                        H Offline
                        Hen
                        wrote on sidst redigeret af
                        #980

                        Genmab (+2,0%, 3233,00) har fået hævet kursmålet til 2650 kr. fra 2490 kr. hos Morningstar. Anbefalingen er trukket i modsat retning og sænket til "sælg" fra "hold".
                        Det fremgik sent mandag af Bloomberg News.

                        1 Reply Last reply
                        0
                        • StockBullS Offline
                          StockBullS Offline
                          StockBull
                          wrote on sidst redigeret af
                          #981

                          34usd er da et nærigt target af MS hvis de samtidig mener Genmab har god mulighed for at vinde voldgiften

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #982

                            Hvis flere af analytikerne er af denne overbevisning, så er det nok grunden til at Genmab har været så stærk på det seneste.

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #983

                              Det ville være så lækkert med 5 års ekstra peaksale fra FastPro - og formentlig ligeså en bedre chance for at Janssen inlicensierer HexaCD38 og driver den frem hvor det giver mening!

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #984

                                Tillige giver det Genmab roen/tiden til at lancerer nye produkter og bliver et fuldt ud integreret pharmaselskab

                                1 Reply Last reply
                                0
                                • StockBullS Offline
                                  StockBullS Offline
                                  StockBull
                                  wrote on sidst redigeret af
                                  #985

                                  Ja det kunne godt tyde på flere analytikere er begyndt at indregne positivt udfald af voldgiften for det kan ikke være øgede forventninger til 2023 revenue der trækker læsset. P.t indikere konsensus lavere revenue for 2023 end for 2022

                                  1 Reply Last reply
                                  0
                                  • StockBullS Offline
                                    StockBullS Offline
                                    StockBull
                                    wrote on sidst redigeret af
                                    #986

                                    23xAnalytiker target og revenue forecast 2023 fra tradingview https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/108171_Skaermbillede_2022_11_29_150015_trading_view.jpg

                                    1 Reply Last reply
                                    0
                                    • StockBullS Offline
                                      StockBullS Offline
                                      StockBull
                                      wrote on sidst redigeret af
                                      #987

                                      revenue skulle være ESP

                                      1 Reply Last reply
                                      0
                                      • R Offline
                                        R Offline
                                        Raun
                                        wrote on sidst redigeret af
                                        #988

                                        Link Preview Image
                                        Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 46%?

                                        Today we will run through one way of estimating the intrinsic value of Genmab A/S ( CPH:GMAB ) by taking the expected...

                                        favicon

                                        (simplywall.st)

                                        1 Reply Last reply
                                        0
                                        • H Offline
                                          H Offline
                                          henrik48
                                          wrote on sidst redigeret af
                                          #989

                                          Tak godt link !!

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper